Re:Almost a third of our portfolio is under attack by patent...
by mseebach on Tuesday January 12, 2010 @06:09AM
(#1047274)
I don't know if that's correct, but if it is, it's patents that make it possible for the universities and NIH to sell the right exclusively.
Since manufacturing, testing and marketing a drug is hysterically expensive, the patent seems to serve a purpose there -- even if pharma companies are more akin to specialized investment bankers than scientists.
Since manufacturing, testing and marketing a drug is hysterically expensive, the patent seems to serve a purpose there -- even if pharma companies are more akin to specialized investment bankers than scientists.